Quick Answer
InMed Pharmaceuticals Inc. reported Cash And Cash Equivalents At Carrying Value of $11.08 million for the year ending 2025.
- InMed Pharmaceuticals Inc. showed an increase of +68.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from InMed Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $4.50 million | Q4 2020: $10.02 million | Q1 2021: $9.45 million | Q2 2021: $7.36 million | Q3 2021: $15.34 million | Q4 2021: $11.28 million | Q1 2022: $5.90 million | Q3 2022: $9.35 million | Q4 2022: $11.45 million | Q1 2023: $9.60 million | Q3 2023: $6.74 million | Q4 2023: $9.53 million | Q1 2024: $7.60 million | Q3 2024: $5.58 million | Q4 2024: $3.42 million | Q1 2025: $4.68 million | Q2 2025: $11.08 million | Q3 2025: $9.33 million | Q4 2025: $6.95 million.
- Over the full 7 years of available data (2019 to 2025), InMed Pharmaceuticals Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 12.6%.
- Historical annual values: Fiscal year 2025: $11.08 million | Fiscal year 2024: $6.57 million | Fiscal year 2023: $8.91 million | Fiscal year 2022: $6.18 million | Fiscal year 2021: $7.36 million | Fiscal year 2020: $5.81 million | Fiscal year 2019: $9.84 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: